THU0355 Efficacy and Safety of Adalimumab in Patients with Ankylosing Spondylitis and Total Spinal Ankylosis in Croatia: One Year Follow-Up

2013 ◽  
Vol 72 (Suppl 3) ◽  
pp. A285.1-A285
Author(s):  
F. Grubišić ◽  
S. Grazio ◽  
Ð. Babić-Naglić ◽  
J. Morović-Vergles ◽  
B. Anić ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Efficacy And Safety ◽  
One Year

Treatment of varicose tributaries with sclerotherapy with polidocanol 0.5 % foam

VASA ◽  
2010 ◽  
Vol 39 (2) ◽  
pp. 169-174 ◽  
Author(s):  
Reich-Schupke ◽  
Weyer ◽  
Altmeyer ◽  
Stücker
Keyword(s):  
Scientific Evidence ◽  
Daily Practice ◽  
Severe Adverse Effect ◽  
Safe Procedure ◽  
Efficacy And Safety ◽  
Foam Sclerotherapy ◽  
History Of ◽  
One Year ◽  
Additional Therapy

Background: Although foam sclerotherapy of varicose tributaries is common in daily practice, scientific evidence for the optimal sclerosant-concentration and session-frequency is still low. This study aimed to increase the knowledge on foam sclerotherapy of varicose tributaries and to evaluate the efficacy and safety of foam sclerotherapy with 0.5 % polidocanol in tributaries with 3-6 mm in diameter. Patients and methods: Analysis of 110 legs in 76 patients. Injections were given every second or third day. A maximum of 1 injection / leg and a volume of 2ml / injection were administered per session. Controls were performed approximately 6 months and 12 months after the start of therapy. Results: 110 legs (CEAP C2-C4) were followed up for a period of 14.2 ± 4.2 months. Reflux was eliminated after 3.4 ± 2.7 injections per leg. Insufficient tributaries were detected in 23.2 % after 6.2 ± 0.9 months and in 48.2 % after 14.2 ± 4.2 months, respectively. Only 30.9 % (34 / 110) of the legs required additional therapy. In 6.4 % vein surgery was performed, in 24.5 % similar sclerotherapy was repeated. Significantly fewer sclerotherapy-sessions were required compared to the initial treatment (mean: 2.3 ± 1.4, p = 0.0054). During the whole study period thrombophlebitis (8.2 %), hyperpigmentation (14.5 %), induration in the treated region (9.1 %), pain in the treated leg (7.3 %) and migraine (0.9 %) occurred. One patient with a history of thrombosis developed thrombosis of a muscle vein (0.9 %). After one year there were just hyperpigmentation (8.2 %) and induration (1.8 %) left. No severe adverse effect occurred. Conclusions: Foam sclerotherapy with injections of 0.5 % polidocanol every 2nd or 3rd day, is a safe procedure for varicose tributaries. The evaluation of efficacy is difficult, as it can hardly be said whether the detected tributaries in the controls are recurrent veins or have recently developed in the follow-up period. The low number of retreated legs indicates a high efficacy and satisfaction of the patients.

Efficacy and safety of laser therapy on axillary hyperhidrosis after one year follow-up: A randomized blinded controlled trial

2015 ◽  
Vol 47 (2) ◽  
pp. 173-179 ◽  
Author(s):  
Franck Marie Leclère ◽  
Javier Moreno-Moraga ◽  
Justo M. Alcolea ◽  
Peter M. Vogt ◽  
Josefina Royo ◽  
...  
Keyword(s):  
Laser Therapy ◽  
Controlled Trial ◽  
Efficacy And Safety ◽  
Axillary Hyperhidrosis ◽  
One Year

Biosimilars in Saudi Arabia: a single-centre, open-label case series examining infliximab switching

2021 ◽  
Vol 10 (2) ◽  
pp. 68-71
Author(s):  
Mansour Somaily ◽  
Hana Alahmari ◽  
Wejdan Abbag ◽  
Shahenda Yousif ◽  
Nawar Tayfour ◽  
...  
Keyword(s):  
Saudi Arabia ◽  
Ankylosing Spondylitis ◽  
Disease Activity ◽  
Activity Index ◽  
Case Series ◽  
Disease Activity Index ◽  
Local Data ◽  
Open Label ◽  
One Year

Background: A biosimilar version of infliximab ( CT-P13) was recently approved for use in Saudi Arabia. Clinical data support its use in the treatment of rheumatic disease, however, there is a lack of local data regarding the efficacy and tolerability of CT-P13 among patients with rheumatological disorders in Saudi Arabia. Objectives: To investigate the feasibility, tolerability and immunogenicity of switching from originator infliximab to biosimilar infliximab, CT-P13, in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and Behçet’s disease (BD). Methodology: The study included patients who were being treated with originator infliximab in the Department of Rheumatology in Khamis Mushayt General Hospital, Saudi Arabia, and were required to switch to biosimilar infliximab (CT-P13) between January 2018 and June 2019. Patient follow-up was carried out every three months for one year. The disease activity score 28 (DAS28) was used to assess RA severity. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score was used to measure disease activity in patients with AS, while BD disease activity was based on clinical assessment. Results: In total, 13 patients (six with RA, five with AS and two with BD) were switched to biosimilar infliximab. The majority (n = 11/13) remained on biosimilar infliximab throughout the follow-up period with no reported major adverse events. Overall, there was a significant improvement in RA disease activity following biosimilar treatment, with the mean DAS28 decreasing from 3.61±1.24 before biosimilar therapy to 2.63±1.54 one year after switching. Conclusion: In patients with AS, BD, or RA who switched from originator infliximab to the biosimilar, CT-P13, we did not observe any significant differences in tolerability or efficacy between biosimilar and originator. Furthermore, disease activity significantly declined in RA patients following biosimilar treatment

Assessment of efficacy and safety of micropulse diode laser treatment in glaucoma: One year follow-up

2020 ◽  
Vol 95 (7) ◽  
pp. 327-333
Author(s):  
C. Logioco ◽  
L.D. Perrone ◽  
D. Caruso ◽  
R. Albertazzi ◽  
G. Valvecchia ◽  
...  
Keyword(s):  
Laser Treatment ◽  
Diode Laser ◽  
Efficacy And Safety ◽  
One Year

One-Year Follow-up of Two Exercise Interventions for the Management of Patients with Ankylosing Spondylitis

2006 ◽  
Vol 85 (7) ◽  
pp. 559-567 ◽  
Author(s):  
C??sar Fern??ndez-de-las-Pe??as ◽  
Cristina Alonso-Blanco ◽  
Isabel Maria Alguacil-Diego ◽  
Juan Carlos Miangolarra-Page
Keyword(s):  
Ankylosing Spondylitis ◽  
Exercise Interventions ◽  
One Year

scholarly journals Long-term efficacy and safety of netakimab in the treatment of ankylosing spondylitis: results of Phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA

2020 ◽  
Vol 14 (4) ◽  
pp. 39-49
Author(s):  
V. I. Mazurov ◽  
Sh. F. Erdes ◽  
I. Z. Gaydukova ◽  
T. V. Dubinina ◽  
A. M. Pristrom ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Phase Iii ◽  
Upper Respiratory Tract ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Interleukin 17A ◽  
Asas Criteria ◽  
Magnetic Resonance Imaging Mri ◽  
Tract Infections

Netakimab (NTK) is a humanized anti-interleukin-17A monoclonal antibody. To date, the drug has been approved to treat ankylosing spondylitis (AS), psoriatic arthritis, and plaque psoriasis. The paper gives the data obtained during 52-week follow-up of AS patients in the phase III ASTERA study.Objective: to study the efficacy and safety of NTK when used long in patients with active AS.Patients and methods. The investigation enrolled 228 patients with active AS, in whom nonsteroidal anti-inflammatory drugs or biological agents were ineffective. The patients were randomized in a 1:1 ratio to receive NTK 120 mg or placebo. The drug was administered subcutaneously at weeks 0, 1, 2, and then once every 2 weeks. Patients who received placebo and achieved a 20% improvement according to the ASAS criteria (ASAS20) were excluded from the study at week 16. At this week, patients who took placebo and did not achieve an ASAS20 response were switched to subcutaneous NTK at 120 mg dose once every two weeks. The follow-up period was 52 weeks.Results and discussion. Patients with active AS who received NTK were more likely to respond to treatment than those who took placebo. The proportion of people who achieved 40% improvement (ASAS40) during treatment with NTK increased throughout the follow-up period and amounted to 80.7% at week 52. Positive changes were achieved in all used clinical and laboratory parameters of AS activity. There was also a decrease in inflammatory changes, as shown by magnetic resonance imaging (MRI). The adverse events (AEs) were mainly laboratory abnormalities and upper respiratory tract infections. Treatment-related AEs were recorded in no more than one third of patients and they were mild to moderate. Severe AEs were singular.Conclusion. Response to NTK therapy generates in the first weeks of drug use and increases throughout a year. The safety profile of NTK when used long is generally favorable.

One-year follow-up of opicapone's efficacy and safety in patients with Parkinson’s disease and motor fluctuations (BIPARK I)

2016 ◽  
Vol 22 ◽  
pp. e100 ◽  
Author(s):  
Joaquim Ferreira ◽  
Andrew Lees ◽  
Ana Santos ◽  
Nelson Lopes ◽  
Jose-Francisco Rocha ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Motor Fluctuations ◽  
Efficacy And Safety ◽  
One Year
Sign in / Sign up

Export Citation Format

Share Document